The purpose of this legislation is to allow patients with life-threatening diseases or severely debilitating illnesses to access investigational individualized medical treatments. These treatments are not yet fully approved by the Food and Drug Administration (FDA) but may offer hope when standard treatment options have been exhausted. Key provisions of the law include defining who qualifies as an "eligible patient" for these treatments. To be eligible, a patient must have a serious illness, have tried all approved treatment options, and be unable to participate in clinical trials.